EGFR and non-small cell lung carcinoma: Some of these so-called tyrosine kinase inhibitors (TKIs), like afatinib, erlotinib, gefitinib, and osimertinib, are already approved for treating patients with EGFR-mutated non-small-cell lung cancer [60].